Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2021

View Archived Issues

Bacteriophage delivery of TNF-alpha gene therapy suppresses chondrosarcoma tumors in vivo

Merck & Co.'s [11C]L-235 can be used to assess target engagement of cathepsin K inhibitors

AbbVie initiates first-in-human study of ABBV-623 and ABBV-992

Nanjing Ruijie Pharma divulges ACC inhibitors

Nerviano Medical Sciences patents IDH inhibitors

Bayer presents new alpha2C-adrenoceptor antagonists

Jiangsu Simcere Pharmaceutical identifies new PRMT5 inhibitors

Shanghai SIMR Biotech synthesizes new PLA2G7 inhibitors

Phase I data for anti-PCSK9 peptide vaccine candidates AT-04A and AT-06A

Second cohort data from phase I/II study of NOX-A12 in glioblastoma multiforme

GPR55 promotes NASH development through ACC activation

EC-11770 shows broad-spectrum activity in nontuberculous mycobacterial infection models

Inflammation, depression share "core biological process"

SPK-10000, a liver-targeted gene therapy for the treatment of hereditary angioedema

Preclinical data show antiviral and anti-inflammatory activity of balixafortide in COVID-19

AB Science suspends inclusion in masitinib trials

Phase IIb study of vamorolone in Duchenne muscular dystrophy meets primary endpoint

FDA clears IND for anti-CD73 antibody HLX-23 for advanced solid tumors

Pivotal study of venglustat in ADPKD stopped for futility

CARB-X supports BioVersys' development of pyrrolocytosines targeting antibiotic-resistant bacteria

Neuren holds pre-IND meetings for phase II trials of NNZ-2591 for neurological disorders

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...